Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation

NCT: NCT07722832 · NOT_YET_RECRUITING

NCT IDNCT07722832
StatusNOT_YET_RECRUITING
Start Date2026-10-01
Completion2028-04-01
SponsorKLAVA Innovation (INDUSTRY)
First posted
Last updated

Brief Summary

As part of post-marketing clinical monitoring and with a view to applying for the digital medical device Quitoxil® to be included on the LPPR list, this prospective, multicentre, controlled, randomised clinical trial aims to evaluate the clinical impact of support provided by Quitoxil® as an adjunct to conventional management for patients undergoing smoking cessation who have a tobacco use disorder.

Frequently Asked Questions

What is Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation?

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation is a clinical trial registered under NCT07722832. Current status: NOT_YET_RECRUITING.

What is the status of NCT07722832?

The current status of NCT07722832 (Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation) is: NOT_YET_RECRUITING.

When did Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation start?

Evaluation of the Efficacy of QUITOXIL® in Smoking Cessation started on 2026-10-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.